CN1245065A - Medicine for treating hepatism - Google Patents
Medicine for treating hepatism Download PDFInfo
- Publication number
- CN1245065A CN1245065A CN 98117279 CN98117279A CN1245065A CN 1245065 A CN1245065 A CN 1245065A CN 98117279 CN98117279 CN 98117279 CN 98117279 A CN98117279 A CN 98117279A CN 1245065 A CN1245065 A CN 1245065A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- amino acids
- group
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A medicine for treating different hepatisms is prepared from compound amino acid, astragalus root, wolfberry fruit, pilose asiabell root, red sage root, jujube and cane sugar as raw materials through conventional process. It features use of 18 amino acids, regulating the ratio of higher branched-chain amino acids to lower aromatic amino acids and high content of high-branched-chain amino acids, and Chinese medicinal materials are added to the mix proportion. Its advantages include low price, providing sufficient heat energy, regenerating liver cells and high curative effect.
Description
The present invention relates to a kind of medicine for the treatment of hepatopathy, specifically a kind of is the medicine that material combination is made with aminoacids complex (being rich in branched-chain amino acid) with Chinese medicine, is applicable to viral hepatitis, alcoholic hepatitis, the treatment of drug induced hepatic injury etc.
At present, the amino acid therapy of hepatopathy is more and more paid attention to for people.At first propose the infull patient of liver function from Fischer the seventies, particularly hepatic encephalopathy patient Proteometabolism is unusual, is that (SURGERY 1975 for the main cause that causes hepatic coma so that cause the blood plasma amino acid imbalance; 73:276).Its viewpoint is that the change of blood plasma aminogram makes interior ArAA of brain and methionine increase and form false neurotransmitter and causes stupor to take place.Based on this theory, and for energy is provided, nutrition and reparation and promote proteinic syntheticly and are manufactured experimently out Freamine (Fischer liquid: FO-80, homemade liver peace by name), the amino acid imbalance when being used to correct hepatic encephalopathy and occurring.
Now be used for hepatopath's products of amino acid abroad, all contain higher branched-chain amino acid, and aromatic amino acid be lower, in order to generation and the doing well,improving that prevents hepatic encephalopathy.Said products costs an arm and a leg, the liver ammonia of making as import drugs looses, and this quasi drugs only contains bright, and is different bright, three kinds of branched-chain amino acid such as figured silk fabrics, and do not contain all the other tens seed amino acids, even the imitative special liver of hepatopathy is pacified 8% injection, still lack necessary aminoacid (egg, phenylpropyl alcohol and color), therefore all belong to unbalanced amino acid preparation, what be only applicable to hepatic encephalopathy stress patient.
The objective of the invention is to: based on hepatopath's vivo acid metabolic balance theory, adjust higher branched-chain amino acid and lower aromatic amino acid ratio according to the hepatopathy characteristics, and be equipped with Chinese medicine, make its various compositions more reasonable, and a kind of medicine for the treatment of hepatopathy is provided, adjust organism metabolism balance, enhancing human body immunity power, alleviate burden of liver being intended to.
Medicine of the present invention is made (consumption is a weight portion) by following component:
Aminoacids complex 10-20 part, Radix Astragali 10-20 part, Fructus Lycii 10-20 part, Radix Codonopsis 5-20 part, Radix Salviae Miltiorrhizae 10-20 part, Fructus Jujubae 10-20 part, sucrose 1-10 part.
Wherein aminoacids complex is formed by following weight portion: aspartic acid 2.32-5.31 part, glycine 5.00-7.25 part, methionine 2.35-5.35 part, threonine 3.15-5.15 part, alanine 5.31-9.21 part, serine 2.57-3.98 part, isoleucine 9.00-14.32 part, cystine 0.15-0.72 part, leucine 8.32-15.32 part, glutamic acid 4.32-10.28 part, valine 8.32-16.31 part, tyrosine 0.15-0.32 part, phenylalanine 0.87-3.17 part, arginine 1.32-3.25 part, lysine 4.11-8.11 part, proline-4 .21-10.15 part, histidine 0.85-1.85 part, tryptophan 0.21-1.32 part.
The optimum weight proportioning of medicine of the present invention is:
11 parts of aminoacids complexs, 14 parts of the Radixs Astragali, 14 parts of Fructus Lyciis, 9 parts of Radix Codonopsis, 16 parts of Radix Salviae Miltiorrhizaes, 16 parts in Fructus Jujubae, 3 parts of sucrose.
Wherein aminoacids complex is formed by following weight portion: 4.46 parts of aspartic acids, 6.38 parts of glycine, 3.21 parts of methionine, 4.15 parts of threonine, 8.11 parts of alanine, 3.17 parts of serines, 12.99 parts of isoleucine, 0.63 part of cystine, 13.87 parts of leucines, 8.30 parts in glutamic acid, 12.23 parts of valines, 0.23 part in tyrosine, 2.07 parts of phenylalanine, arginase 12 .58 part, 6.11 parts of lysines, 5.64 parts of proline, 1.07 parts of histidine, 0.77 part of tryptophan.
Above-mentioned each component is made medicine production technology of the present invention all adopt conventional manufacture method preparation.
The present invention and FO-80 liquid phase ratio contain branched-chain amino acid, and the former accounts for 40.81% of total amino acids, and the latter accounts for 33.88%; Contain aromatic amino acid, the former is 3.2%, latter position 2.1%.And the former also contains all the other tens seed amino acids, sees table five for details.
Experimentation of the present invention: with the rat acute hepatic injury due to the galactosamine is animal model, raise with the present invention, and with liver ammonia loose (Tianjin pharmacy two factories of central authorities) compare, observe symptom, survival, liver function and the amino acid whose variation respectively organized before and after the rat experiment.
Material and method: with the rat of selecting for use, body weight 200-300 gram is divided into four groups at random, and each organizes 30, and experimental group A organizes (raising with the present invention), B group (raise with liver ammonia and loose), and C organizes (raising with common food), and D organizes (intraperitoneal injection of saline).Raised back 24 hours, and got 10 blood samplings for every group, survey serum glutamic pyruvic transminase, aminoacid, protein content.All the other continue to observe death and symptom.
The experimental result symptom: the injection galactosamine is after 24 hours, and it is not too obvious that each organizes symptom, beginning in about 38 hours, and each organizes the symptom that drowsiness and similar stupor in various degree appears in rat, and increases the weight of in time.Death (survival) as shown in Table 1.
Changes of liver function: the injection galactosamine is after 24 hours, and the Serum ALT value obviously raises (except the blank group), and As time goes on, different variation such as table two appear in each lab A LT value, shown in the table three.
Each organizes the variation of rat blood serum aminogram: each organizes rat in the variation of injecting 24 hours later blood sampling analysis of amino acid content of galactosamine as shown in Table 4.
, survive from symptom by above result: the A group of respectively organizing, changes of liver function, serum amino acid props up/fragrant ratio, all is better than the C group, and similar with the B group.
For showing the therapeutic effect of medicine of the present invention to hepatopathy, the present invention selects 50 routine patients to carry out clinical experiment in three tame hospitals, male's 29 examples wherein, women's 21 examples, the oldest 78 years old, minimum 24 years old.2 examples more than 20 years old, 14 examples more than 30 years old, 14 examples more than 40 years old, 10 examples more than 50 years old, 10 examples more than 60 years old.
Diagnostic criteria Western medicine diagnose standard, symptom is: feel sick, detest greasyly, diet is poor, abdominal distention, pain in the hepatic region, weak, become thin, hepatic facies, liver palm, splenomegaly or promptly toward history of virus hepatitis, existing obviously sick; Laboratory inspection: abnormal liver function, B ultrasonic is unusual.The tcm diagnosis standard, symptom is: weak, become thin, feel sick and detest oil, the abdominal distention loose stool, anorexia, right rib is pain down, hepatic facies.
MethodsThe cases enrolled standard: all abnormal liver function or promptly toward having hepatitis history or primary symptom that five above persons are arranged.
Instructions of taking: oral, each one bag, every day three times.
Curative effect determinate standard symptom curative effect produce effects: after taking one month continuously, transference cure is more than 2/3rds; Effectively: after taking one month continuously, transference cure is more than 1/3rd; The laboratory is checked: liver function recovery normally is a produce effects, transfers to well effectively.
Through clinical 50 routine result on trial, produce effects 33 examples account for sum 66%; Effective 17 examples account for sum 34%.Clinical observation shows, safety of the present invention effectively, has no side effect, taking convenience, and patient's symptom curative effect and feeling takes a turn for the better obviously.The embodiment of the invention: aminoacids complex when making granule, earlier with Chinese crude drug-lixiviate-separation-concentrated-spray drying, then is mixed into the granule pack with aminoacid powder for directly buying; When making oral liquid, operation is Chinese crude drug decoction-filtration, with aminoacid powder miscible-filtration-bottling (10 milliliters every bottle)-sterilization-packing.
Table one: each organizes the survival of rats situation
A group (30) 20 (adopted 10 17 11 11 in first day second day the 3rd day the 4th day
Only) B group (30) 20 (adopt 10 18 10 10
Only) C group (30) 20 (adopt 10 16 80
Only) D group (30) 20 (adopt 10 20 20 20
Only)
Table two: each organizes the rat blood serum liver function
A group B group C group D group
ALT 178±42 224±70 325±65 19±5.6
P<0.01 P<0.05 P<0.001
TP 46.2±8.5 38.8±7.2 31.7±8.2 58.4±4.2
P<0.05 P>0.05 P<0.001
ALB 39.2±3.2 30.1±4.0 26.4±2.1 42.4±3.2
P<0.05 P<0.05 P<0.01
Table three: each organizes rat blood serum liver function n=10 over time
ALT TP ALB
The one the second the three the one the second the three the one the second three
Everyday the sky everyday A organize 162 153 32 ± 44 ± 39.2 31.2 32.1 35.1 24.2
±45 ±42 15 35 ±18 ±18 ±19 ±20 ±13
P<0. P<0. P<0. P>0. P>0. P>0. P>0. P>0. P>0.
01 01 01 05 05 05 05 05 05B organize 200 215 21 ± 36 ± 37.2 62.1 35.5 33.4 31.1
±78 ±34 20 16 ±25 ±25 ±28 ±22 ±17
P<0. P<0. P<0. P>0. P>0. P<0. P>0. P>0. P>0.
05 05 01 05 05 01 05 05 05C organize 362 413 239 38.4 19.2 18.4 35.4 39.1 25.1
± ± ± ±27 ±18 ±18 ±15 ±8 ±19
185 145 102D group 17 ± 27 ± 28 ± 58.1 42.1 52.2 42.9 48.9 49.1
15 20 15 ±18 ±25 ±20 ±25 ±21 ±25
P<0. P<0. P<0. P>0. P>0. P<0. P>0. P>0. P>0.
01 01 01 05 05 01 05 05 05
Table four: each organize rat blood serum aminogram n=10 aminoacid title A group B group C group D group taurine 269.9 ± 194.5 ± 212 ± 23.9 151.5 ±
29.5 38.5 18.5 aspartic acid 28.5 ± 3.1 20.7 ± 9.6 28.1 ± 11.3 21.9 ± 9.6 threonine 642.6 ± 642 ± 291 531.6 ± 366.4 ±
121.3 60.7 38.7 serine 153.3 ± 154.5 ± 133 ± 20.8 107.4 ±
25.5 70.5 42.2 glutamic acid 182 ± 10.4 171.5 ± 158 ± 16.4 98.6 ± 17.8
47.5 glycine 321 ± 55.8 298 ± 134 229.3 ± 184.7 ±
31.8 32.4 alanine 339.3 ± 336.5 ± 254.6 ± 200.3 ±
85.5 164.5 47.4 40.2 cystines 52.3 ± 13.1 28.9 ± 10.7 29.3 ± 11.0 14.1 ± 10.2 valines 108 ± 11.4 86.4 ± 36.4 77.0 ± 2.9 79.1 ± 3.1 methionine 471 ± 7.5 38.5 ± 11.5 32.8 ± 3.9 28.2 ± 4.2 isoleucine 51.2 ± 5.8 38.9 ± 16.3 38.7 ± 1.8 37.9 ± 1.0 leucine 108.9 ± 89.2 ± 41.8 83.8 ± 6.1 87.4 ± 5.3
10.7 tyrosine 63.9 ± 10.5 43.2 ± 10.9 85.8 ± 0.7 24 ± 1.4 phenylalanine 42.7 ± 2.8 38.7 ± 8.2 71.9 ± 10.6 34.9 ± 8.9 ornithine 107.6 ± 5.9 87.3 ± 34.6 78 ± 13.6 25.8 ± 12.1 lysine 146.7 ± 171.1 ± 130 ± 46.1 172.3 ±
32.3 123.9 32.8 histidines 44.2 ± 11.3 32.5 ± 9.1 36.4 ± 0.7 27.0 ± 1.8 tryptophan 40.1 ± 3.9 56.9 ± 9.5 48.3 ± 6.1 42.7 ± 7.8 arginine 9.8 ± 7.7 5.6 ± 5.6 46.2 ± 49 83.8 ± 32 proline 106.7 ± 106.3 ± 107 ± 48.2 155.9 ±
27.3 37.8 42.3BCAA/AAA 2.5±0.04 2.5±0.6 1.3±0.3 3.5±0.8
P<0.001 P<0.01 P<0.01P value is propped up/fragrant ratio and C group comparative result for each group rat plasma aminoacid
Table five: the aminoacid of the present invention and FO-80 liquid is formed content relatively
FO-80 liquid (%) the present invention (%) isoleucine 10.74 13.56 leucines 13.12 14.48 valines 10.02 12.27BCAA 33.88 40.81 phenylalanines 1.19 2.16 tyrosine 0.24 tryptophan 0.91 0.80AAA 2.10 3.20BCAA/AAA 3.80 20.00
Claims (2)
1. a medicine for the treatment of hepatopathy is characterized in that it is to form by following materials of weight proportions: aminoacids complex 10-20 part, Radix Astragali 10-20 part, Fructus Lycii 10-20 part, Radix Codonopsis 5-20 part, Radix Salviae Miltiorrhizae 10-20 part, Fructus Jujubae 10-20 part, sucrose 1-10 part;
Wherein aminoacids complex is formed by following weight proportion: aspartic acid 2.32-5.31 part, glycine 5.00-7.25 part, methionine 2.35-5.35 part, threonine 3.15-5.15 part, alanine 5.31-9.21 part, serine 2.57-3.98 part, isoleucine 9.00-14.32 part, cystine 0.15-0.72 part, leucine 8.32-15.32 part, glutamic acid 4.32-10.28 part, valine 8.32-16.31 part, tyrosine 0.15-0.32 part, phenylalanine 0.87-3.17 part, arginine 1.32-3.25 part, lysine 4.11-8.11 part, proline-4 .21-10.15 part, histidine 0.85-1.85 part, tryptophan 0.21-1.32 part.
2. the medicine of treatment hepatopathy according to claim 1 is characterized in that the weight proportion of each raw material is: 11 parts of aminoacids complexs, 14 parts of the Radixs Astragali, 14 parts of Fructus Lyciis, 9 parts of Radix Codonopsis, 16 parts of Radix Salviae Miltiorrhizaes, 16 parts in Fructus Jujubae, 3 parts of sucrose;
Wherein aminoacids complex is formed by following weight proportion: 4.46 parts of aspartic acids, 6.38 parts of glycine, 3.21 parts of methionine, 4.15 parts of threonine, 8.11 parts of alanine, 3.17 parts of serines, 12.99 parts of isoleucine, 0.63 part of cystine, 13.87 parts of leucines, 8.30 parts in glutamic acid, 12.23 parts of valines, 0.23 part in tyrosine, 2.07 parts of phenylalanine, arginase 12 .58 part, 6.11 parts of lysines, 5.64 parts of proline, 1.07 parts of histidine, 0.77 part of tryptophan.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98117279A CN1087616C (en) | 1998-08-14 | 1998-08-14 | Medicine for treating hepatism |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98117279A CN1087616C (en) | 1998-08-14 | 1998-08-14 | Medicine for treating hepatism |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1245065A true CN1245065A (en) | 2000-02-23 |
CN1087616C CN1087616C (en) | 2002-07-17 |
Family
ID=5225441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98117279A Expired - Fee Related CN1087616C (en) | 1998-08-14 | 1998-08-14 | Medicine for treating hepatism |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1087616C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101014334B (en) * | 2004-07-14 | 2011-01-05 | 味之素株式会社 | Inhibitor for the onset and progress of liver cancer to be used in hepatitis c virus-positive human liver cirrhosis patients |
US8197860B2 (en) | 2005-06-23 | 2012-06-12 | Nuliv Holding Inc. | Method for enhancing nutrient absorption with astragalosides |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003296176A1 (en) * | 2002-12-26 | 2004-07-22 | Ajinomoto Co., Inc. | Inhibitor for liver cancer onset and progress |
-
1998
- 1998-08-14 CN CN98117279A patent/CN1087616C/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101014334B (en) * | 2004-07-14 | 2011-01-05 | 味之素株式会社 | Inhibitor for the onset and progress of liver cancer to be used in hepatitis c virus-positive human liver cirrhosis patients |
US8197860B2 (en) | 2005-06-23 | 2012-06-12 | Nuliv Holding Inc. | Method for enhancing nutrient absorption with astragalosides |
Also Published As
Publication number | Publication date |
---|---|
CN1087616C (en) | 2002-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102145128B (en) | Medicinal composition for preventing and treating cardiac and cerebral vascular diseases and preparation method thereof | |
CN1224691C (en) | Medical wine for invigorating vital function of kidney and its preparing process | |
CN104623201B (en) | A kind of liver protection Elmination of toxicant and fat-lowering hypoglycemic medicine and its application | |
CN102160884B (en) | Chinese medicinal preparation for treating acute period vital myocarditis | |
CN1087616C (en) | Medicine for treating hepatism | |
CN1233395C (en) | Oral liquid for treating postpartum hypogalactia and its preparation | |
CN1253786A (en) | Fresh deer's blood health-care medicated wine and its preparation method | |
CN1411838A (en) | Medicine for curing diabetes | |
CN103599259B (en) | A kind of Dai Nationality's medicament extract preparation and application thereof with hypoglycemic activity | |
CN1169564C (en) | New medicine for curing diobetes | |
CN1264519C (en) | Notoginseng total saponin amino acid transfusion liquid and its producing method | |
CN1042597C (en) | Vision-brighting and blood sugar decreasing composition and its produciton | |
CN1081065C (en) | Compound oral liquid of cactus | |
CN1121869C (en) | Sugar-correcting capsule | |
CN1490036A (en) | Chemical for promoting growth of hairs and preventnig sinility | |
CN101647876B (en) | Antiviral compound traditional Chinese medicament and preparation method thereof | |
CN1846763A (en) | Medicine composition for treating coronary heart disease and its prepn process | |
CN1079658A (en) | A kind of traditional Chinese medicine powder capsule for treating chronic ischemic heart disease | |
CN1695695A (en) | Oral liquid of royal jelly of ginseng and hairy antler, and preparation method | |
CN1233359C (en) | Compound Jigucao capsule (Abrus fruticulosus Wall. ex Wight et Arn.) and its prodn. method | |
CN105920288B (en) | Improve Chinese medicine preparation of insulin resistance syndrome and preparation method and application | |
CN1593574A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
CN115531482A (en) | Application of ginseng root-strengthening oral liquid in preparation of medicines for preventing and treating hypoproteinemia | |
CN104706815A (en) | Wolfberry-pseudo-ginseng health composition | |
CN1602918A (en) | Astragalus root and Breviscapine containing Chinese medicinal formulation and its preparation and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |